Global report - September 3, 2017
First excessive pricing investigation on the pharma sector
The European Commission (EC) opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines. The formal investigation address concerns that Aspen Pharma has engaged in excessive pricing concerning five life-saving cancer medicines. The Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules. “When we get sick, […]
Global report - September 1, 2017
Historic approval for Novartis
Novartis has received a FDA approval for its CAR-T treatment tisagenlecleucel, a first-ever cell therapy for a rare form of acute lymphoblastic leukemia. The US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up […]
Global report - August 23, 2017
Merck CEO quits Trump’s manufacturing council
The CEO of global pharma giant Merck, Kenneth Frazier, is resigning from President Donald Trump’s manufacturing council. The resignation came after a weekend of violence at a white-nationalist and neo-Nazi protest in Charlottesville, Virginia. The president did not explicitly condemn white supremacists. In a statement Frazier said: “America’s leaders must honor our fundamental values by […]
Global report - August 14, 2017
EMA prepares for Brexit
The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the United Kingdom’s withdrawal from the European Union and the Agency’s relocation. “Preparing for the move, managing the necessary changes, and addressing challenges such as possible losses in skilled and experienced staff, […]
Global report - July 6, 2017
Trump’s first Presidency: Impact on U.S. Life Sciences
Proposed drastic cuts to U.S. science agencies and departments by President Donald Trump have life science researchers on edge about the fate of current and future projects, not to mention the nation’s standing in the scientific community.
Global report - April 24, 2017
Astellas gathers all corporate support functions to Denmark
The global pharmaceutical company Astellas has gathered all corporate support functions to its Nordic and Baltic sales units in Denmark. “In Stockholm, 90 percent of our employees would be Swedish, in Oslo they would be Norwegian, and in Finland they would be Finns. But in Copenhagen, we have employees with four Nordic nationalities, with a […]